FAM
NMRA icon

Fred Alger Management’s Neumora Therapeutics NMRA Stock Holding History

Fred Alger Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,177
Closed -$39.7K – 492
2025
Q4 		$39.7K Buy
+22,177
New +$48.6K ﹤0.01% 459

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Fred Alger Management's NMRA Position: Q1 2026 in Review

Fred Alger Management sold out of Neumora Therapeutics (NMRA) in Q1 2026, closing a stake of 22,177 shares — an estimated $39.7K sold.

Fred Alger Management first reported a position in NMRA in Q4 2025 and held it in 1 quarter. The position peaked at $39.7K in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Fred Alger Management reported no remaining Neumora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fred Alger Management sold 22,177 Neumora Therapeutics shares in Q1 2026, an estimated $39.7K.
  • Fred Alger Management first reported a position in Neumora Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fred Alger Management's Neumora Therapeutics position peaked at $39.7K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.